Lung Cancer Clinical Trials in Tennessee

Showing 681-688 of 688 trials

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00088088

This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.

Stage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

Synta Pharmaceuticals Corp.86 participantsStarted Mar 2004

Jonesboro, Arkansas, United States • Pomona, California, United States • San Francisco, California, United States +16 more locations

COMPLETEDPhase 129 miles

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504

This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.

Advanced Solid TumorsNon Small Cell Lung Cancer

Pfizer49 participantsStarted Jul 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +2 more locations

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Lung Cancer Trials in Other Cities

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Tennessee